Your browser is no longer supported. Please, upgrade your browser.
Cerus Corporation
Index- P/E- EPS (ttm)-0.36 Insider Own2.40% Shs Outstand171.24M Perf Week1.84%
Market Cap1.06B Forward P/E- EPS next Y-0.33 Insider Trans-0.43% Shs Float167.16M Perf Month-8.56%
Income-61.30M PEG- EPS next Q-0.10 Inst Own87.30% Short Float6.33% Perf Quarter21.56%
Sales130.10M P/S8.14 EPS this Y28.30% Inst Trans-0.02% Short Ratio8.92 Perf Half Y4.28%
Book/sh0.49 P/B12.43 EPS next Y8.30% ROA-27.90% Target Price9.00 Perf Year-5.29%
Cash/sh0.71 P/C8.62 EPS next 5Y- ROE-62.90% 52W Range4.67 - 8.87 Perf YTD-11.99%
Dividend- P/FCF- EPS past 5Y8.90% ROI-38.60% 52W High-27.73% Beta1.16
Dividend %- Quick Ratio2.30 Sales past 5Y27.30% Gross Margin61.90% 52W Low37.26% ATR0.20
Employees270 Current Ratio2.80 Sales Q/Q41.00% Oper. Margin-45.40% RSI (14)58.51 Volatility2.82% 3.28%
OptionableYes Debt/Eq0.76 EPS Q/Q0.90% Profit Margin-47.10% Rel Volume1.12 Prev Close6.09
ShortableYes LT Debt/Eq0.65 EarningsAug 03 AMC Payout- Avg Volume1.19M Price6.41
Recom1.40 SMA203.48% SMA503.37% SMA2004.18% Volume1,328,981 Change5.25%
Oct-08-20Resumed BTIG Research Buy $9
Jun-16-20Resumed Cantor Fitzgerald Overweight $9
Feb-26-20Initiated BTIG Research Buy $7
Nov-13-19Upgrade BTIG Research Neutral → Buy $7
Aug-28-19Initiated Stifel Buy
Aug-23-19Resumed Stephens Overweight
Jan-05-18Resumed Cantor Fitzgerald Overweight
Dec-08-17Resumed BTIG Research Neutral
Jul-07-16Resumed Cantor Fitzgerald Buy $9
Dec-17-15Downgrade Wedbush Outperform → Neutral
May-02-14Reiterated MLV & Co Buy $8.50 → $6
Apr-24-13Reiterated Cantor Fitzgerald Buy $5.50 → $6
Mar-15-13Reiterated MLV & Co Buy $7.50 → $8.50
Apr-17-12Initiated Cantor Fitzgerald Buy $5.50
Feb-29-12Upgrade Robert W. Baird Neutral → Outperform $3 → $6
Nov-10-11Reiterated MLV & Co Buy $4 → $5
Jun-03-11Initiated Wedbush Outperform $4
Mar-04-11Downgrade Robert W. Baird Outperform → Neutral $4 → $3
Mar-09-10Upgrade Robert W. Baird Neutral → Outperform $3 → $5
Aug-26-09Upgrade Avondale Mkt Perform → Mkt Outperform $2 → $5
Oct-19-21 08:00AM  
Oct-18-21 12:26PM  
Oct-07-21 06:49AM  
Oct-01-21 08:00AM  
Sep-20-21 08:00AM  
Sep-15-21 08:00AM  
Aug-15-21 01:26PM  
Aug-10-21 08:30AM  
Aug-04-21 08:30AM  
Aug-03-21 05:15PM  
Jul-27-21 03:02PM  
Jul-20-21 08:30AM  
Jul-14-21 08:30AM  
Jun-30-21 08:30AM  
Jun-14-21 08:30AM  
Jun-05-21 04:16AM  
May-17-21 09:00AM  
May-05-21 09:30AM  
May-04-21 05:35PM  
Apr-20-21 08:30AM  
Apr-06-21 02:46AM  
Mar-03-21 08:30AM  
Feb-26-21 10:01AM  
Feb-25-21 04:01PM  
Feb-24-21 05:00PM  
Feb-11-21 08:30AM  
Feb-05-21 01:39AM  
Feb-04-21 08:30AM  
Jan-23-21 11:30PM  
Jan-11-21 08:30AM  
Dec-15-20 08:30AM  
Dec-11-20 10:55PM  
Dec-07-20 12:11AM  
Dec-04-20 07:00PM  
Nov-30-20 12:00PM  
Nov-20-20 12:00PM  
Nov-12-20 08:30AM  
Nov-01-20 07:59AM  
Oct-30-20 03:30PM  
Oct-29-20 06:05PM  
Oct-28-20 10:13AM  
Oct-22-20 12:34PM  
Oct-19-20 08:30AM  
Oct-13-20 08:30AM  
Sep-28-20 08:30AM  
Sep-16-20 07:49AM  
Sep-09-20 08:30AM  
Aug-26-20 01:08PM  
Aug-25-20 08:38AM  
Aug-12-20 09:26AM  
Aug-11-20 06:48AM  
Aug-07-20 08:30AM  
Aug-05-20 02:01AM  
Aug-04-20 05:15PM  
Jul-30-20 08:30AM  
Jul-28-20 12:33PM  
Jul-23-20 08:30AM  
Jul-07-20 08:30AM  
Jul-06-20 10:01AM  
Jun-24-20 03:17PM  
Jun-17-20 11:30AM  
Jun-15-20 05:43PM  
Jun-12-20 08:30AM  
Jun-11-20 09:39AM  
May-27-20 12:00PM  
May-26-20 08:30AM  
May-07-20 12:15PM  
May-06-20 07:33AM  
May-05-20 06:45PM  
May-04-20 08:30AM  
Apr-29-20 10:05AM  
Apr-28-20 12:34PM  
Apr-24-20 08:30AM  
Apr-23-20 11:43AM  
Apr-20-20 05:50PM  
Apr-07-20 08:40AM  
Apr-06-20 08:30AM  
Apr-02-20 08:30AM  
Mar-26-20 08:30AM  
Mar-02-20 04:56PM  
Feb-25-20 03:25PM  
Feb-22-20 07:58AM  
Feb-20-20 04:01PM  
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Swisher Daniel N JRDirectorAug 04Option Exercise2.8612,87736,828106,231Aug 05 05:08 PM
Swisher Daniel N JRDirectorAug 04Sale6.2512,87780,48193,354Aug 05 05:08 PM
Greenman William MarinerPresident and CEOAug 03Option Exercise2.08100,000208,0001,518,672Aug 05 05:12 PM
Swisher Daniel N JRDirectorMay 18Option Exercise2.905,00014,50064,868May 20 07:21 PM
Swisher Daniel N JRDirectorMay 18Sale5.755,00028,73559,868May 20 07:21 PM
CORASH LAURENCE MChief Scientific OfficerApr 30Option Exercise3.6625,20092,2321,982,586May 04 09:12 PM
Greenman William MarinerPresident and CEOApr 16Option Exercise2.70550,0001,485,0001,652,531Apr 20 09:15 PM
Jayaraman Vivek KChief Operating OfficerMar 15Sale6.3837,149236,925148,332Mar 16 07:43 PM
Green Kevin DennisChief Financial OfficerMar 15Sale6.3829,331187,064109,745Mar 16 07:39 PM
Greenman William MarinerPresident and CEOMar 15Sale6.38156,407997,517975,257Mar 16 07:37 PM
CORASH LAURENCE MChief Scientific OfficerMar 15Sale6.3823,775151,6301,942,605Mar 16 07:34 PM
Benjamin Richard JChief Medical OfficerMar 15Sale6.3649,331313,84452,040Mar 16 07:32 PM
Menard ChrystalChief Legal OfficerMar 15Sale6.3829,331187,06461,858Mar 16 07:29 PM
Moore CarolSVP Reg. & QualityMar 15Sale6.3829,331187,064135,560Mar 16 07:25 PM
Swisher Daniel N JRDirectorFeb 16Option Exercise2.9010,00029,00069,868Feb 18 06:46 PM
Swisher Daniel N JRDirectorFeb 16Sale7.7810,00077,79759,868Feb 18 06:46 PM
Menard ChrystalChief Legal OfficerFeb 08Option Exercise4.338,12535,14252,752Feb 11 05:59 PM
Menard ChrystalChief Legal OfficerFeb 08Sale8.008,12565,00048,585Feb 11 05:59 PM
ANDERSON TIMOTHY BDirectorDec 22Option Exercise5.4030,000162,000240,101Dec 28 05:39 PM
Jayaraman Vivek KChief Operating OfficerDec 22Option Exercise4.3256,105242,400188,440Dec 28 05:44 PM
Menard ChrystalChief Legal OfficerDec 22Option Exercise4.37211,327923,379134,001Dec 28 05:43 PM
ANDERSON TIMOTHY BDirectorDec 22Sale8.3139,336326,856200,765Dec 28 05:39 PM
Jayaraman Vivek KChief Operating OfficerDec 22Sale8.0056,105448,840135,003Dec 28 05:44 PM
Menard ChrystalChief Legal OfficerDec 22Sale8.00211,3271,690,61648,585Dec 28 05:43 PM
SCHULZE GAILDirectorDec 14Option Exercise2.4815,00037,20062,393Dec 15 08:51 PM
SCHULZE GAILDirectorDec 14Sale7.3262,393456,8170Dec 15 08:51 PM
Menard ChrystalChief Legal OfficerDec 11Option Exercise4.4341,363183,38370,460Dec 15 08:49 PM
Jayaraman Vivek KChief Commercial OfficerDec 11Option Exercise4.3318,89581,815178,898Dec 15 08:44 PM
Menard ChrystalChief Legal OfficerDec 11Sale8.0041,363330,90448,585Dec 15 08:49 PM
Jayaraman Vivek KChief Commercial OfficerDec 11Sale8.0043,895351,160135,003Dec 15 08:44 PM
Swisher Daniel N JRDirectorNov 17Option Exercise2.9010,00029,00069,868Nov 19 05:07 PM
Swisher Daniel N JRDirectorNov 17Sale6.2510,00062,50559,868Nov 19 05:07 PM
Green Kevin DennisChief Financial OfficerNov 10Sale5.4932,928180,86299,468Nov 12 06:57 PM